Navigation Links
ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
Date:10/29/2008

udio archive will be available at the same address until November 12, 2008.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward looking statements in this press release include the Company's financial guidance for 2008, and statements regarding ViroPharma's clinical development programs, including
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
4. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
5. ViroPharma Provides Update on Vancocin(R)
6. ViroPharma Augments Senior Management
7. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
8. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
9. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. ViroPharma to Present at the Maxim Group First Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , ... September 03, 2015 , ... ... and Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for ... institutions will train at CHC as part of fulfilling their requirements for obtaining ...
(Date:9/3/2015)... Georgia (PRWEB) , ... September 03, 2015 , ... ... spread of disease in Haiti, has partnered with Slingshot® Product Development Group to ... electricity or running water. Michael Wahl with DriButts plans to bring 600 DriButts ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... care community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado ... 2016, and has been carefully designed to serve up to 80 people living ...
(Date:9/3/2015)... ... September 03, 2015 , ... IQ Formulations ... 2015 by economic development group GrowFL and the Edward Lowe Foundation. The leading ... for this prestigious award, which recognizes growing second-stage companies “that demonstrate high performance ...
Breaking Medicine News(10 mins):Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3
... , ... skin brightener, has now introduced anti aging ingredients to its already popular product to make ... ... SkinBright the most complete skin brightener available. , , ,Age spots, liver spots, brown patches, ...
... ... to grow, unethical companies are beginning to produce imitation products to benefit from the success ... phony products before they become too large to control. , ... Milford, CT (PRWEB) March 16, 2010 -- They say imitation ...
... ... Marketing Excellence Europe Conference explores how global medical device manufacturers are leveraging integrated, domain-specific ... ... 16, 2010 -- Model N , the leader in Revenue Management solutions for ...
... ... income in the current economy, and who are looking to better their health, too, can ... enlisting interested business leaders nationwide., , ... (PRWEB) March 16, 2010 -- Independent businessman Brad Aspin and leading health and wellness ...
... NANJING , March 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... leading pharmaceutical company,specializing in the development, manufacturing, and marketing of ... for the quarter and the fiscal year ended December ... -- Total revenue was RMB539.4 million (US$79.0 million) ...
... Fla. , March 15 ARMSRx ... leader in transparent pharmacy benefits assessment, has received many requests ... the first quarter closes in 2010.  The September 26, ... First DataBank (FDB) and Medispan may very well leave employers ...
Cached Medicine News:Health News:Best Selling, Non Toxic Skin Brightener Does the Job Using Safe, Healthy Ingredients and Introduces New Anti Aging Ingredients 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 3Health News:Media Alert: Model N and International Medical Device Leader to Share Insights on Maximizing Sales Performance with Revenue Management 2Health News:Brad Aspin and Health and Wellness Company GBG Now Looking for Leaders Nationwide 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 14Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 15Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 16Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 17Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 18Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 19Health News:ARMSRx Evaluation of AWP Neutrality 2Health News:ARMSRx Evaluation of AWP Neutrality 3
(Date:9/3/2015)... About dry eye syndrome Dry eye ... deficient tear production or quick tear evaporation or deviation ... aqueous tear deficient dry eye and evaporative dry eye. ... not produce enough tears, whereas meibomian gland dysfunction results ... slow tear evaporation and maintain tear stability. The symptoms ...
(Date:9/3/2015)... , Sept. 3, 2015  WellCare Health Plans, Inc. ... Asher , senior vice president and chief financial officer, ... 2015 Healthcare Conference on Wednesday, September 9, 2015, at ... be webcast live. In addition, a replay of the ... live broadcast. Both the live broadcast and the replay ...
(Date:9/3/2015)... ALISO VIEJO, Calif. , Sept. 3, ... a leading global pharmaceutical company, and AqueSys, Inc. ... on developing ocular implants that reduce intraocular pressure ... have entered into an agreement under which Allergan ... the terms of the agreement, Allergan will acquire ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
... (NYSE Euronext Paris: COX) today announced that the ... with OA of the hip showed a highly,statistically ... of the trial. Naproxcinod 750 mg bid showed ... similar blood pressure profile,to placebo. Naproxcinod is the ...
... Nov. 21 Millions of Americans with moderate to severe ... new treatment option. Today, Johnson & Johnson Pharmaceutical Research ... Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief ... of age or older. , , ...
Cached Medicine Technology:Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 2Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 3Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 4Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
Inquire...
... CHEK test is a rapid immunoassay to detect ... specimens. The test uses antibodies specific for toxins ... >90% sensitivity and >99% specificity compared to tissue ... and toxin B, the risk of false negative ...
Medicine Products: